Gilead Science公司在2025年第4季度比收入估计数高,提出了2026年的指导意见,并提升了其红利。 Gilead Sciences beat earnings estimates in Q4 2025, raised 2026 guidance, and boosted its dividend.

据Gilead Science公司报告,2026年2月10日的第四季度收入高于预期,达到186 EPS和79.3亿美元的收入,超过了估计。 Gilead Sciences reported stronger-than-expected fourth-quarter earnings on February 10, 2026, with $1.86 EPS and $7.93 billion in revenue, surpassing estimates. 该公司将其2026年全年指导提高到8.45至8.85美元的EPS,指出其艾滋病毒和抗病毒产品表现良好,并取得编审进展。 The company raised its 2026 full-year guidance to $8.45–$8.85 EPS, citing strong performance in its HIV and antiviral products and pipeline progress. 分析员提升了价格目标,机构投资者增加了持有量。 Analysts upgraded price targets, and institutional investors increased holdings. 股票开放时为154.98美元,交易额高于关键的移动平均数,波动性低,股息增加到每股0.82美元。 The stock opened at $154.98, trading above key moving averages, with a low-volatility profile and a dividend increase to $0.82 per share.